"New England Cancer Specialists is a physician-owned, patient-centered medical practice, recognized as a leader in cancer patient care, treatment, and research. With nearly half of Maine’s medical oncologists and hematologists on our team, we are the region’s largest oncology group, serving people in need throughout New England."

During the past decade, Maine Center for Cancer Medicine-Kennebunk conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Maine Center for Cancer Medicine-Kennebunk" #1 sponsor was "National Cancer Institute (NCI)" with 6 trials, followed by "Alliance for Clinical Trials in Oncology" with 2 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 2 trials sponsored, "Alliance Foundation Trials, LLC." with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Maine Center for Cancer Medicine-Kennebunk" #1 collaborator was "National Cancer Institute (NCI)" with 4 trials as a collaborator, "Canadian Cancer Trials Group" with 1 trials as a collaborator, "Division of Cancer Control" with 1 trials as a collaborator, "Janssen Research & Development, LLC" with 1 trials as a collaborator and "NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Maine Center for Cancer Medicine-Kennebunk" are "Invasive Breast Carcinoma" (3 trials), "Stage IB Lung Non-Small Cell Carcinoma AJCC v7" (3 trials), "Stage II Lung Non-Small Cell Cancer AJCC v7" (3 trials), "Stage IIIA Lung Non-Small Cell Cancer AJCC v7" (3 trials) and "Anatomic Stage II Breast Cancer AJCC v8" (2 trials). Many other conditions were trialed in "Maine Center for Cancer Medicine-Kennebunk" in a lesser frequency.

Most popular intervention types in "Maine Center for Cancer Medicine-Kennebunk" are "Drug" (8 trials), "Other" (8 trials), "Biological" (7 trials), "Procedure" (6 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Biospecimen Collection" (4 trials), "Computed Tomography" (4 trials), "Laboratory Biomarker Analysis" (4 trials), "Nivolumab" (4 trials) and "Clinical Observation" (3 trials). Other intervention names were less common.

The vast majority of trials in "Maine Center for Cancer Medicine-Kennebunk" are 10 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Maine Center for Cancer Medicine-Kennebunk". undefined are not yet recruiting, 5 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Maine Center for Cancer Medicine-Kennebunk, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Maine Center for Cancer Medicine-Kennebunk, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".